Hormonal Aromatase Inhibitor (AI)FDA-approved medicinePrescription drug

Aromasin (Exemestane)

Exemestane

Evidence: Approved label. Example dose: finalize with a provider. Not a fact-check stamp.

12.5mg – 12.5 mg Oral Daily or EOD

Steroidal AIIrreversible (Suicidal) InhibitorFDA-Approved

Exemestane, marketed as Aromasin, is an orally active steroidal aromatase inhibitor (AI) developed by Pharmacia & Upjohn and approved by the FDA in 1999 for the treatment of estrogen-receptor-positive breast cancer in postmenopausal women. It is a 6-methylenandrosta-1,4-diene-3,17-dione derivative - structurally an androstenedione analog - that binds irreversibly to the aromatase enzyme and inactivates it, earning it the informal label of suicidal or suicide inhibitor within the AI class.

Quick Start

Route

Oral

Start low

12.5mg Oral

Frequency

Daily or EOD

Timing

Take with food

Take with food to optimize absorption (~40% higher AUC fed vs fasted). Dosing is typically 12.5mg every other day to 25mg daily depending on the aromatizable steroid dose. Start low - crashing estrogen causes joint pain, low libido, depression, and lipid damage. Confirm dose with a pre-cycle E2 baseline and a mid-cycle E2 (sensitive assay) check.

❋

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first

Conservative start

12.5mg · Oral · Daily or EOD

conservative starter

12.5mg

Daily or EOD

Intermediate

Suicidal AI Estrogen Control

12.5 mg · Oral · 2x Weekly

human clinical trial · FDA Aromasin label

Must be taken with a fat-containing meal for proper absorption. Dose exclusively based on bloodwork.

12.5 mg

2x Weekly

◆

How it works

Aromatase is the CYP19A1 enzyme that converts androgens (testosterone, androstenedione) into estrogens (estradiol, estrone). Exemestane is an androstenedione analog that binds the aromatase active site and is then converted by the enzyme itself into a reactive intermediate that covalently modifies and permanently inactivates the enzyme. Restoration of aromatase activity therefore requires de novo synthesis of new enzyme rather than simple displacement.

In postmenopausal women, peripheral aromatization in fat, skin, and muscle is the dominant estrogen source; exemestane 25mg daily produces roughly 85-98% suppression of whole-body aromatization and plasma estradiol. In men on aromatizable steroid cycles, a similar suppression translates to tight estrogen control through a stable blood-level curve without the rebound spikes seen with reversible AIs when doses are missed.

Exemestane also has weak androgenic activity of its own - it is structurally related to androstenedione and retains mild AR-binding - which is why it does not fully crash HDL the way strong reversible AIs tend to, and why some users report modest anabolic feel during use. Endogenous testosterone typically rises modestly through reduced estrogen negative feedback at the HPT axis.

What to expect

Early

Days 1–7

First 3-7 days: steady-state tissue aromatase suppression builds as irreversibly inactivated enzyme accumulates. Estrogen-related water weight and blood pressure often begin to drop.

Mid

Weeks 2–4

Weeks 2-4: estrogen stabilizes at the dose-dependent set point. Gynecomastia symptoms resolve in most users if dose is appropriate. This is the window to draw a sensitive E2 and adjust.

Later

Weeks 4–12

Beyond 4 weeks on a stable dose: estrogen remains steady. Bone density and lipids should be monitored on long runs. Post-cycle recovery of aromatase function takes 1-2 weeks.

Evidence

HumanModerate

AnimalPresent

In-vitroModerate

Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.

Dose/mechanism boundary: in postmenopausal women with advanced breast cancer, oral exemestane 25 mg/day inactivated peripheral aromatase by about 98% — a disease- and population-specific pharmacodynamic finding, not a general safety statement. (Adverse-event data are covered separately — see companion citation for this PMID.)

Oral exemestane 25 mg/day inactivates peripheral aromatase activity (approximately 98% inactivation) and reduces basal plasma estrone, estradiol and estrone sulphate levels by 85 to 95% in postmenopausal women with advanced breast cancer.

Exemestane. Drugs · 1999 · PMID 10551437

Evidence scope. Human, postmenopausal women with advanced breast cancer only; enzyme-inactivation (PD) finding, not demonstrated in other populations and not itself a safety statement.

Primary safety: common adverse events at the studied 25 mg/day regimen were hot flushes, nausea, and fatigue.

Other common adverse events are hot flushes, nausea and fatigue.

Exemestane. Drugs · 1999 · PMID 10551437

Evidence scope. Human, postmenopausal women with advanced breast cancer, oral 25 mg/day; AE list specific to this population and dose.

Mechanism: exemestane is a mechanism-based steroidal aromatase inhibitor that produces prolonged aromatase inhibition.

Mechanism-based steroidal inhibitors such as 4-hydroxyandrostenedione and exemestane produce prolonged aromatase inhibition in patients.

Aromatase, aromatase inhibitors, and breast cancer. American journal of therapeutics · 2001 · PMID 11550075

Evidence scope. General multi-drug aromatase-inhibitor review; exemestane specifically named; mechanism-level claim only, no dose/population attached.

Claims we could not support

No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.

Dose/frequency: 12.5 mg orally daily or every other day. The checked abstracts support the approved 25 mg/day regimen, not 12.5 mg daily/EOD.

Side effects & safety

Commonly reported

Joint pain and stiffness (dose-related, worsens with over-suppression)
Reduced libido and erectile quality if E2 is over-suppressed
Mild fatigue or flat mood with low E2
Hot flashes (more common in women; occurs in men with crashed E2)
Mild lipid shift (less severe than non-steroidal AIs)

Less common & notes

Dry skin and eyes, insomnia, headache, decreased bone mineral density on long-term use, mild elevation of liver enzymes, hair thinning.
Rare but reportable: severe depression with over-suppression, significant osteopenia or fractures on multi-year adjuvant use, hypersensitivity reactions.
Crashing estrogen below ~15 pg/mL for extended periods is the primary cause of symptomatic side effects in men on cycle.

Pharmacokinetics

Illustrative plasma concentration · 4 d

Half-life

~24 hours

Peak · Tmax

1-2 hours

Elimination

4-5 days

Bioavailability

~42%

Oral (~40% higher when taken with food)

Duration of action

Functional aromatase suppression persists for days beyond the half-life due to irreversible binding - supports daily or every-other-day dosing

Clearance

Hepatic (CYP3A4 primary, aldo-keto reductases). Fecal and urinary excretion of metabolites.

Storage. Store at controlled room temperature (20-25°C / 68-77°F). Protect from moisture and light. Keep in original container. Shelf life typically 3 years from manufacture date. Keep out of reach of children.

Regulatory status

Prescription medication (Rx) in the United States. FDA-approved brand: Aromasin (Pfizer). Generic exemestane widely available. Not a controlled substance. Off-label use in men for estrogen control during AAS cycles or TRT is common but legally requires a valid prescription. Internationally classified as a prescription drug in most jurisdictions.

Put it to work

Calculate, log & track

Open Aromasin (Exemestane) straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open Aromasin (Exemestane) in the app →

Go deeper

The guide & community

The complete Aromasin (Exemestane) walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗

Open in app Community